Actinium Pharmaceuticals (ATNM) Gets a Buy from H.C. Wainwright
November 15 2022 - 06:15AM
TipRanks
In a report released today, Joseph Pantginis from H.C. Wainwright
reiterated a Buy rating on Actinium Pharmaceuticals (ATNM -
Research Report), with a price target of $53.00. The company's
shares closed yesterday at $12.51.Pantginis covers the Healthcare
sector, focusing on stocks such as Palatin Technologies, Actinium
Pharmaceuticals, and PDS Biotechnology. According to TipRanks,
Pantginis has an average return of -16.9% and a 30.95% success rate
on recommended stocks. Currently, the analyst consensus on Actinium
Pharmaceuticals is a Strong Buy with an average price target of
$30.00, implying a 139.81% upside from current levels.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-gets-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Feb 2023 to Mar 2023
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Mar 2022 to Mar 2023
